Heterocyclic compound and use thereof

Abstract

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.A compound represented by the formula (I):wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

1 . A compound represented by the formula (I): 
       
         
           
           
               
               
           
         
         wherein 
         R 1  is an optionally substituted C 1-6  alkyl group, an optionally substituted mono- or di-C 1-6  alkylamino group, an optionally substituted C 3-6  cycloalkyl group, or an optionally substituted 3- to 14-membered non-aromatic heterocyclic group; 
         R 2  is a hydrogen atom, a fluorine atom, an optionally substituted C 1-6  alkyl group, or an optionally substituted C 3-6  cycloalkyl group; 
         R 3  is an acyl group, an optionally substituted C 1-6  alkyl group, an optionally substituted C 3-6  cycloalkyl group, an optionally substituted C 6-14  aryl group, an optionally substituted 3- to 14-membered non-aromatic heterocyclic group, or an optionally substituted 5- to 14-membered aromatic heterocyclic group; and 
         Ring A is an optionally further substituted C 6-14  aromatic hydrocarbon ring, or an optionally further substituted 5- to 14-membered aromatic heterocycle, 
         or a salt thereof. 
       
     
     
         2 . The compound or salt according to  claim 1 , wherein
 R 1  is   (1) a C 1-6  alkyl group,   (2) a mono- or di-C 1-6  alkylamino group, or   (3) a C 3-6  cycloalkyl group;   R 2  is   (1) a hydrogen atom,   (2) a fluorine atom, or   (3) a C 1-6  alkyl group;   R 3  is   (1) a C 1-6  alkyl-carbonyl group optionally substituted by 1 to 3 substituents selected from
 (a) a halogen atom, 
 (b) a hydroxy group, and 
 (c) a cyano group, 
   (2) a C 1-6  alkoxy-carbonyl group,   (3) a C 3-10  cycloalkyl-carbonyl group (the C 3-10  cycloalkyl moiety of the C 3-10  cycloalkyl-carbonyl group is optionally bridged) optionally substituted by 1 to 3 substituents selected from
 (a) a halogen atom, 
 (b) a hydroxy group, 
 (c) a cyano group, and 
 (d) a C 1-6  alkyl group, 
   (4) a 3- to 14-membered non-aromatic heterocyclylcarbonyl group optionally substituted by 1 to 3 substituents selected from
 (a) a halogen atom, 
 (b) a hydroxy group, and 
 (c) a C 1-6  alkyl group, 
   (5) a mono- or di-C 1-6  alkyl-carbamoyl group,   (6) a N—C 1-6  alkyl-N—C 1-6  alkoxy-carbamoyl group, or   (7) a N—C 1-6  alkyl-N′,N′-di-C 1-6  alkylhydrazine-carbonyl group; and   Ring A is   (1) a benzene ring   further substituted by one substituent selected from
 (a) a C 6-14  aryl group optionally substituted by 1 to 3 substituents selected from
 (i) a halogen atom, 
 (ii) an optionally halogenated C 1-6  alkyl group, and 
 (iii) an optionally halogenated C 1-6  alkoxy group, and 
 
 (b) a 5- to 14-membered aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from
 (i) a C 1-6  alkyl group optionally substituted by 1 to 3 substituents selected from a halogen atom and a hydroxy group, 
 (ii) a C 1-6  alkoxy group, 
 (iii) a halogen atom, and 
 (iv) a C 1-6  alkoxy-carbonyl group, and 
 
   optionally further substituted by 1 to 3 halogen atoms, or   (2) a 5- or 6-membered aromatic heterocycle further substituted by one C 6-14  aryl group optionally substituted by 1 to 3 halogen atoms.   
     
     
         3 . The compound or salt according to  claim 1 , wherein
 R 1  is   (1) a C 1-6  alkyl group,   (2) a mono- or di-C 1-6  alkylamino group, or   (3) a C 3-6  cycloalkyl group;   R 2  is   (1) a hydrogen atom, or   (2) a fluorine atom;   R 3  is (1) a C 1-6  alkyl-carbonyl group optionally substituted by 1 to 3 hydroxy groups,   (2) a C 3-10  cycloalkyl-carbonyl group (the C 3-10  cycloalkyl moiety of the C 3-10  cycloalkyl-carbonyl group is optionally bridged) optionally substituted by 1 to 3 substituents selected from
 (a) a halogen atom, and 
 (b) a hydroxy group, 
   (3) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group, or   (4) a mono- or di-C 1-6  alkyl-carbamoyl group; and   Ring A is a benzene ring   further substituted by one C 6- i 4  aryl group optionally substituted by 1 to 3 substituents selected from
 (i) a halogen atom, and 
 (ii) an optionally halogenated C 1-6  alkyl group, and 
   optionally further substituted by 1 to 3 halogen atoms.   
     
     
         4 . The compound or salt according to  claim 1 , wherein
 R 1  is   (1) a C 1-6  alkyl group, or   (2) a mono- or di-C 1-6  alkylamino group;   R 2  is   (1) a hydrogen atom, or   (2) a fluorine atom;   R 3  is   (1) a C 1-6  alkyl-carbonyl group optionally substituted by 1 to 3 hydroxy groups,   (2) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group, or   (3) a mono- or di-C 1-6  alkyl-carbamoyl group; and   Ring A is a benzene ring   further substituted by one C 6-14  aryl group optionally substituted by 1 to 3 substituents selected from
 (i) a halogen atom, and 
 (ii) a C 1-6  alkyl group, and 
   optionally further substituted by 1 to 3 halogen atoms.   
     
     
         5 .- 7 . (canceled) 
     
     
         8 . A medicament comprising the compound or salt according to  claim 1 . 
     
     
         9 . The medicament according to  claim 8 , which is an orexin type 2 receptor agonist. 
     
     
         10 .- 11 . (canceled) 
     
     
         12 . A method of activating an orexin type 2 receptor in a mammal, which comprises administering an effective amount of the compound or salt according to  claim 1  to the mammal. 
     
     
         13 . A method for the prophylaxis or treatment of narcolepsy in a mammal, which comprises administering an effective amount of the compound or salt according to  claim 1  to the mammal. 
     
     
         14 . (canceled)